Technical Analysis for ONCT - Oncternal Therapeutics, Inc.

Grade Last Price % Change Price Change
C 8.26 -11.56% -1.08
ONCT closed down 11.56 percent on Friday, April 9, 2021, on 1.73 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical ONCT trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Calm After Storm Range Contraction 0.00%
Calm After Storm Range Contraction -11.56%
Inside Day Range Contraction -11.56%
Wide Bands Range Expansion -11.56%
New 52 Week Closing High Bullish -12.03%
Pocket Pivot Bullish Swing Setup -12.03%
Volume Surge Other -12.03%
Wide Range Bar Range Expansion -12.03%
New 52 Week High Strength -12.03%
Older End-of-Day Signals for ONCT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits about 5 hours ago
Gap Down Partially Closed about 23 hours ago
20 DMA Support about 24 hours ago
10 DMA Support about 24 hours ago
60 Minute Opening Range Breakout about 24 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Oncternal Therapeutics, Inc. Description

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Solid Tumors Treatment Of Cancer Cancers Chemical Compounds Organic Compounds Monoclonal Antibody Drug Development Sarcoma Treatment Of Cancers Hematologic Cancers

Is ONCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 10.55
52 Week Low 1.49
Average Volume 1,613,900
200-Day Moving Average 4.15
50-Day Moving Average 7.33
20-Day Moving Average 8.38
10-Day Moving Average 8.40
Average True Range 0.90
ADX 23.59
+DI 28.93
-DI 20.73
Chandelier Exit (Long, 3 ATRs ) 7.86
Chandelier Exit (Short, 3 ATRs ) 8.14
Upper Bollinger Band 9.51
Lower Bollinger Band 7.25
Percent B (%b) 0.45
BandWidth 26.97
MACD Line 0.47
MACD Signal Line 0.45
MACD Histogram 0.0201
Fundamentals Value
Market Cap 184.58 Million
Num Shares 22.3 Million
EPS -1.81
Price-to-Earnings (P/E) Ratio -4.56
Price-to-Sales 17.77
Price-to-Book 3.80
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.15
Resistance 3 (R3) 10.21 9.65 9.84
Resistance 2 (R2) 9.65 9.17 9.62 9.73
Resistance 1 (R1) 8.95 8.87 9.30 8.89 9.62
Pivot Point 8.39 8.39 8.56 8.36 8.39
Support 1 (S1) 7.69 7.91 8.04 7.63 6.90
Support 2 (S2) 7.13 7.61 7.10 6.79
Support 3 (S3) 6.43 7.13 6.69
Support 4 (S4) 6.37